Lupin gains after robust Q4 results

Lupin rose 1.2% to Rs 1,652.05 at 15:17 IST on BSE after consolidated net profit rose 47.5% to Rs 807.10 crore on 34% growth in net sales to Rs 4091.30 crore in Q4 March 2016 over Q4 March 2015.

The result was announced during market hours today, 19 May 2016.

Meanwhile, the S&P BSE Sensex was down 308.67 points or 1.2% at 25,395.94.

On BSE, so far 3.25 lakh shares were traded in the counter as against average daily volume of 3.41 lakh shares in the past one quarter. The stock was volatile. The stock surged as much as 3.4% at the day's high of Rs 1,688 so far during the day. The stock rose 0.3% at the day's low of Rs 1,637.45 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past one month till 18 May 2016, gaining 3.9% compared with Sensex's 0.43% fall. The scrip had, however, underperformed the market in past one quarter, declining 8.14% as against Sensex's 8.69% rise.

The large-cap company has equity capital of Rs 90.14 crore. Face value per share is Rs 2.

Commenting on the company's financial performance, Nilesh Gupta, Managing Director of Lupin said that Q4 March 2016 witnessed robust growth across all key markets. Record approvals and significant launches have enabled Lupin to deliver its best results yet and the company is back on the growth path, Gupta said. He said that the company will continue to ramp up its investments in research and is focused on building pipelines in niche high-value areas such as inhalation, biosimilars and complex injectables.

The Q4 March 2016 results are not strictly comparable with Q4 March 2015 results due to the acquisition of GAVIS Pharmaceuticals LLC, USA, Novel Laboratories, Inc., USA and VGS Holdings, Inc., USA (GAVIS) with effect from 8 March 2016.

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News